Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer EU approval

This article was originally published in The Tan Sheet

Executive Summary

The European Commission has approved Bayer's acquisition of Roche's consumer unit, the firms announce Nov. 19. Bayer's enhanced segment now includes Supradyn multivitamins, topical ointment Bepanthen, antacid Rennie and vitamin C supplement Redoxon. The transaction is valued at $3.1 bil. and closing is expected by year-end, Bayer said. As a condition of approval, the EC is requiring Roche to sell regional rights to several of its products, including antifungals Caldesene and Desenex in Ireland and Aspro and Aspro C in Austria. Roche announced its intention to sell its consumer unit to Bayer in July, the same day it announced the licensing of U.S. marketing rights to weight-loss drug Xenical to GlaxoSmithKline (1"The Tan Sheet" July 26, 2004, p. 3)...
Advertisement
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS097531

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel